QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
July 19 2022 - 4:05PM
Business Wire
- QIAGEN Clinical Insights platform growing at over 35% annually,
or 700,000 additional cases, and recently breaking through three
million cases analyzed and reported
- Total number of analyzed and reported patient cases using QCI
five times higher than other commercial offerings
- Unique Augmented Molecular Intelligence approach provides
customers with the ability to scale NGS testing with
confidence
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced that its decision-support software platform QIAGEN
Clinical Insights (QCI) has been used to interpret more than three
million patient molecular profiles for hereditary and oncological
diseases to date. This milestone for the QCI portfolio of clinical
software and professional services for the interpretation and
reporting of variants from next-generation sequencing (NGS) testing
underscores QIAGEN’s leadership position in precision medicine. The
platform, incepted only seven years ago, is currently growing at
35% or 700,000 additional cases per annum, outperforming other
commercial offerings by a factor 5 in terms of patient cases.
The QCI portfolio is an integrated, universal solution for
secondary and tertiary analysis in molecular pathology, clinical
genetics and translational research that can be used with any
sequencing platform. Consisting of QCI Secondary Analysis, QCI
Interpret and QCI Precision Insights, the portfolio streamlines NGS
data analysis and variant interpretation, enabling users to go from
raw NGS data to clinical report swiftly and confidently.
“Surpassing three million patient cases reported using our QCI
solution demonstrates how pervasive our bioinformatics solutions
are becoming in the standard of care for patients. This is in line
with our ambition to deliver on the promise of precision medicine,”
says Executive VP of QIAGEN Digital Insights Jonathan Sheldon. “The
cost and speed of NGS testing is no longer the barrier to uptake.
It’s the downstream analysis, interpretation and quality reporting
of the complex results that is becoming the bottleneck, which is
where our QCI portfolio fits in. Labs can adopt and scale NGS with
confidence with our NGS interpretation and reporting tools using
our advanced augmented molecular intelligence (AMI), no matter
which sequencing platform they use. Today over 200 scientific
experts work alongside machines to efficiently curate, annotate and
analyze complex clinical evidence essential for accurate and
high-quality reporting. This focus on the human effort, review and
certification is critical. It means our customers can trust the
data and proceed with confidence with the most up-to-date
information.”
The content core of the QCI portfolio, the QIAGEN Knowledge
Base, is powered by AMI. It combines artificial intelligence (AI)
and human expertise to advance and accelerate confident clinical
decision-making. A key differentiator of the QCI portfolio, the
application of AMI leverages AI and machine learning to efficiently
identify, extract and align evidence from scientific literature and
over 40 public and proprietary databases in the QIAGEN Knowledge
Base. The approach ensures high-quality molecular intelligence that
users can trust to augment their own decisions.
“One of the biggest challenges of comprehensive genomic
profiling (CGP) is bioinformatics. QIAGEN’s QCI Interpret software
has enabled our lab to confidently scale from a targeted panel with
177 genes to a CGP panel with 718 genes, all while helping us
reduce cost, time, and labor,” said Petr Starostik, MD, Director of
Molecular Pathology, University of Florida Health Pathology
Laboratories. “The content quality of the QIAGEN Knowledge Base is
unrivalled in the industry. From a large complex panel, we can
filter and classify variants according to AMP and NCCN guidelines
and build custom, patient-specific reports with the latest
diagnostic, prognostic and therapeutic information. With so much
data to deal with now, QCI Interpret delivers the insight we need
to make the right decisions.”
With the NGS industry set for significant transformation through
the introduction of lower cost and faster NGS instruments, it is
expecting to see an accelerated adoption of genetic analysis,
testing and screening. As more vendors enter the market, the
customer demand towards dedicated applications and solutions
considering front end sample processing and downstream
bioinformatics will further accelerate. QIAGEN has built an
extensive NGS application and portfolio strength aligned with key
market drivers to fulfill these demands and will continue to invest
in expanding to support the industry growth and complete Sample to
Insight solutions for its customers and partners.
Learn more about the QCI portfolio here.
About QIAGEN Digital Insights
QIAGEN Digital Insights, the bioinformatics business of QIAGEN,
is the leading provider of genomic and clinical knowledge, analysis
and interpretation tools and services for scientists and
clinicians. We have over 25 years of experience in the industry,
90,000 users worldwide, over 100,000 citations in scientific
papers, more than 3 million profiled patient cases and over 40
billion scientific data points. Discover our portfolio of expertly
curated genomic and clinical knowledge solutions as well as
bioinformatics software and services for efficient data management,
sharing and actionable insights. Learn more at
https://digitalinsights.qiagen.com/.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in molecular diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of March 31,
2022, QIAGEN employed more than 6,000 people in over 35 locations
worldwide. Further information can be found at
https://www.qiagen.com/.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220719005866/en/
QIAGEN Investor Relations John Gilardi +49 2103 29
11711 Phoebe Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024